Share on StockTwits

Research analysts at FBR Capital Markets began coverage on shares of Gilead Sciences (NASDAQ:GILD) in a research report issued on Thursday. The firm set an “outperform” rating on the stock.

Gilead Sciences (NASDAQ:GILD) traded up 2.53% on Thursday, hitting $96.36. The stock had a trading volume of 12,343,462 shares. Gilead Sciences has a 52-week low of $55.96 and a 52-week high of $94.61. The stock’s 50-day moving average is $89.23 and its 200-day moving average is $80.98. The company has a market cap of $145.7 billion and a price-to-earnings ratio of 21.29. Gilead Sciences also was the target of a large growth in short interest in July. As of July 31st, there was short interest totalling 98,473,543 shares, a growth of 3.1% from the July 15th total of 95,485,621 shares. Based on an average trading volume of 14,643,274 shares, the short-interest ratio is presently 6.7 days. Approximately 6.5% of the shares of the company are short sold.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Wednesday, July 23rd. The company reported $2.36 earnings per share for the quarter, beating the analysts’ consensus estimate of $1.73 by $0.63. The company had revenue of $6.53 billion for the quarter, compared to the consensus estimate of $5.68 billion. During the same quarter last year, the company posted $0.50 earnings per share. Gilead Sciences’s revenue was up 136.1% compared to the same quarter last year. On average, analysts predict that Gilead Sciences will post $8.02 earnings per share for the current fiscal year.

In other Gilead Sciences news, Director Richard James Whitley unloaded 5,000 shares of Gilead Sciences stock on the open market in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $91.00, for a total transaction of $455,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

A number of other analysts have also recently weighed in on GILD. Analysts at Argus initiated coverage on shares of Gilead Sciences in a research note on Monday. They set a “buy” rating and a $110.00 price target on the stock. Separately, analysts at Zacks upgraded shares of Gilead Sciences from a “neutral” rating to an “outperform” rating in a research note on Thursday, August 7th. They now have a $111.00 price target on the stock. Finally, analysts at Zacks downgraded shares of Gilead Sciences from an “outperform” rating to a “neutral” rating in a research note on Wednesday, August 6th. They now have a $97.00 price target on the stock. One analyst has rated the stock with a hold rating and twenty have assigned a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $103.32.

Gilead Sciences, Inc (NASDAQ:GILD) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.